JAK-STAT Pathway Activation in Malignant and Non-Malignant Cells Contributes to MPN Pathogenesis and Therapeutic Response

The identification of JAK2/MPL mutations in patients with myeloproliferative neoplasms (MPN) led to the clinical development of JAK kinase inhibitors, including ruxolitinib. Ruxolitinib reduces splenomegaly and systemic symptoms in myelofibrosis (MF) and improves overall survival; however the mechan...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Cancer Discov
Main Authors: Kleppe, Maria, Kwak, Minsuk, Koppikar, Priya, Riester, Markus, Keller, Matthew, Bastian, Lennart, Hricik, Todd, Bhagwat, Neha, McKenney, Anna Sophia, Papalexi, Efthymia, Abdel-Wahab, Omar, Rampal, Raajit, Marubayashi, Sachie, Chen, Jonathan J., Romanet, Vincent, Fridman, Jordan S., Bromberg, Jacqueline, Teruya-Feldstein, Julie, Murakami, Masato, Radimerski, Thomas, Michor, Franziska, Fan, Rong, Levine, Ross L.
Formato: Artigo
Idioma:Inglês
Publicado: 2015
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4355105/
https://ncbi.nlm.nih.gov/pubmed/25572172
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-14-0736
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares